SCHEMBL6920771

SCHEMBL6920771

CC1(C)CNc2nc3cc(-c4ccccn4)ccc3c(=O)n2C1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
CYP3A4 P08684 1/20 0.39
METAP2 P50579 2/20 0.39
POLB P06746 1/20 0.38
PIK3CA P42336 7/20 0.38
PIK3CD O00329 4/20 0.38
PIK3CG P48736 4/20 0.38
PIK3CB P42338 3/20 0.38
MAPK10 P53779 1/20 0.37
TGFBR1 P36897 1/20 0.37
PRMT5 O14744 2/20 0.36
WDR77 Q9BQA1 1/20 0.36
CTSD P07339 1/20 0.35
BACE1 P56817 1/20 0.35
DHODH Q02127 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12059073 0.83 NPC1 (0.40) KDM4EALDH1A1HSD17B10CYP3A4METAP2
SCHEMBL14239415 0.82 RAB9A (0.41) KDM4EALDH1A1HSD17B10CYP3A4METAP2
SCHEMBL6922413 0.81 NPC1 (0.43) KDM4EALDH1A1HSD17B10CYP3A4METAP2
SCHEMBL6922591 0.81 CYP3A4 (0.41) CYP3A4METAP2PIK3CAPIK3CDPIK3CG
SCHEMBL14239134 0.80 KMT2A (0.39) CYP3A4METAP2PIK3CAPIK3CDPIK3CG
SCHEMBL6922610 0.80 CYP3A4 (0.40) CYP3A4METAP2PIK3CAPIK3CDPIK3CG
SCHEMBL2051009 0.80 POLB (0.44) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL12059030 0.80 NPC1 (0.42) KDM4EALDH1A1HSD17B10CYP3A4METAP2
SCHEMBL6923262 0.79 RAB9A (0.46) KDM4EALDH1A1HSD17B10CYP3A4POLB
SCHEMBL6921660 0.79 CYP3A4 (0.38) CYP3A4METAP2PIK3CAPIK3CDPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 KDM4E 2003/4885ALDH1A1 1721/4885HPGD 1390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.